Galera Therapeutics Inc
OTC:GRTX
Income Statement
Earnings Waterfall
Galera Therapeutics Inc
Income Statement
Galera Therapeutics Inc
| Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||||||||
| Interest Expense |
1
|
2
|
3
|
4
|
4
|
5
|
5
|
5
|
5
|
6
|
7
|
8
|
10
|
11
|
12
|
13
|
15
|
14
|
11
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | ||||||||||||||||||||||||||
| Operating Expenses |
(36)
|
(43)
|
(51)
|
(58)
|
(65)
|
(68)
|
(71)
|
(70)
|
(74)
|
(78)
|
(73)
|
(69)
|
(60)
|
(53)
|
(51)
|
(52)
|
(57)
|
(55)
|
(47)
|
(40)
|
(27)
|
(18)
|
(14)
|
(18)
|
(14)
|
|
| Selling, General & Administrative |
(7)
|
(7)
|
(8)
|
(10)
|
(12)
|
(14)
|
(16)
|
(17)
|
(18)
|
(20)
|
(21)
|
(21)
|
(21)
|
(20)
|
(20)
|
(22)
|
(26)
|
(26)
|
(23)
|
(19)
|
(13)
|
(11)
|
(11)
|
(10)
|
(8)
|
|
| Research & Development |
(29)
|
(36)
|
(42)
|
(48)
|
(52)
|
(54)
|
(55)
|
(53)
|
(55)
|
(58)
|
(52)
|
(48)
|
(39)
|
(32)
|
(31)
|
(30)
|
(31)
|
(29)
|
(24)
|
(18)
|
(12)
|
(6)
|
(3)
|
(2)
|
(0)
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(2)
|
(2)
|
0
|
0
|
(6)
|
(6)
|
|
| Operating Income |
(36)
N/A
|
(43)
-21%
|
(51)
-17%
|
(58)
-15%
|
(65)
-11%
|
(68)
-5%
|
(71)
-4%
|
(70)
+0%
|
(74)
-5%
|
(78)
-6%
|
(73)
+6%
|
(69)
+6%
|
(60)
+13%
|
(53)
+12%
|
(51)
+2%
|
(52)
-1%
|
(57)
-9%
|
(55)
+3%
|
(47)
+15%
|
(40)
+15%
|
(27)
+32%
|
(18)
+35%
|
(14)
+20%
|
(18)
-24%
|
(14)
+18%
|
|
| Pre-Tax Income | ||||||||||||||||||||||||||
| Interest Income Expense |
0
|
(1)
|
(1)
|
(2)
|
(3)
|
(3)
|
(4)
|
(4)
|
(5)
|
(6)
|
(7)
|
(8)
|
(10)
|
(10)
|
(11)
|
(13)
|
(14)
|
(12)
|
(10)
|
(6)
|
(2)
|
0
|
1
|
0
|
0
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(2)
|
(2)
|
0
|
0
|
(2)
|
(6)
|
0
|
0
|
|
| Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
|
| Pre-Tax Income |
(36)
N/A
|
(44)
-22%
|
(52)
-18%
|
(60)
-16%
|
(67)
-12%
|
(71)
-6%
|
(74)
-5%
|
(75)
0%
|
(78)
-5%
|
(84)
-7%
|
(81)
+4%
|
(77)
+4%
|
(69)
+10%
|
(63)
+10%
|
(62)
+1%
|
(65)
-4%
|
(71)
-10%
|
(70)
+1%
|
(59)
+15%
|
(46)
+23%
|
(29)
+36%
|
(20)
+32%
|
(19)
+3%
|
(16)
+15%
|
(13)
+18%
|
|
| Net Income | ||||||||||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(36)
|
(44)
|
(52)
|
(60)
|
(67)
|
(71)
|
(74)
|
(75)
|
(78)
|
(84)
|
(81)
|
(77)
|
(69)
|
(63)
|
(62)
|
(64)
|
(71)
|
(70)
|
(59)
|
(46)
|
(29)
|
(20)
|
(19)
|
(16)
|
(13)
|
|
| Net Income (Common) |
(43)
N/A
|
(52)
-20%
|
(59)
-14%
|
(65)
-10%
|
(70)
-8%
|
(72)
-2%
|
(74)
-3%
|
(75)
0%
|
(78)
-5%
|
(84)
-7%
|
(81)
+4%
|
(77)
+4%
|
(69)
+10%
|
(63)
+10%
|
(62)
+1%
|
(64)
-4%
|
(71)
-10%
|
(70)
+1%
|
(59)
+15%
|
(46)
+23%
|
(29)
+36%
|
(20)
+33%
|
(19)
+3%
|
(16)
+15%
|
(13)
+18%
|
|
| EPS (Diluted) |
-1.78
N/A
|
-2.09
-17%
|
-2.38
-14%
|
-2.63
-11%
|
-2.82
-7%
|
-2.89
-2%
|
-2.98
-3%
|
-2.99
0%
|
-3.08
-3%
|
-3.18
-3%
|
-3.12
+2%
|
-2.88
+8%
|
-2.58
+10%
|
-2.36
+9%
|
-2.3
+3%
|
-1.83
+20%
|
-1.64
+10%
|
-1.53
+7%
|
-1.33
+13%
|
-0.84
+37%
|
-0.53
+37%
|
-0.36
+32%
|
-0.35
+3%
|
-0.16
+54%
|
-0.13
+19%
|
|